Table 2.
Costs of lipid and blood pressure-lowering pharmaceuticals
| |
Unit price (2008A$) |
Number of units |
Sources and assumptions |
||
|---|---|---|---|---|---|
| Government | Patient | Year 1 | Year 2+ | ||
|
Pharmaceutical costs |
|
||||
| Annual cost of low-dose diuretic therapy |
$52.03 |
$18.79 |
1 |
1 |
Average annual PBS cost for the standard daily dose
[24] of hydrochlorothiazide, chlorthalidone and indapamide, weighted by scripts provided in 2008
[23]. |
| Annual cost of calcium channel blocker therapy |
$163.66 |
$54.22 |
1 |
1 |
Average annual PBS cost for the standard daily dose
[24] of verapimil, amlodopine (maleate), nifedipine, felodipine, amlodopine (besylate) and lercanidipine,weighted by scripts provided in 2008
[23]. |
| Annual cost of ACE inhibitor therapy |
$130.85 |
$81.21 |
1 |
1 |
Average annual PBS cost for the standard daily dose
[24] ofcaptopril, fosinopril, enalopril, ramipril, quinapril, lisinopril, trandolopril and perindopril, weighted by scripts provided in 2008
[23]. |
| Annual cost of beta-blocker therapy |
$169.59 |
$47.09 |
1 |
1 |
Average annual PBS cost for the standard daily dose
[25]of fluvastatin, simvastatin, atorvastatin, pravastatin and rosuvastatin, weighted by scripts provided in 2008
[23]. |
| Annual cost of statin therapy |
$508.64 |
$178.79 |
1 |
1 |
Average annual PBS cost for the standard daily dose
[25] of fluvastatin, simvastatin, atorvastatin, pravastatin and rosuvastatin, weighted by scripts provided in 2008
[23]. |
| Annual cost of statin therapy in New Zealand |
$18.25 |
− |
1 |
1 |
Average annual cost of simvastatin (40 mg/day) in New Zealand
[38]. |
| Annual cost of current practice lipid-lowering therapy |
$559.68 |
$123.37 |
1 |
1 |
Average annual cost from actual PBS expenditure on lipid-lowering drugs in 2008
[23]. |
| Annual cost of current practice blood pressure-lowering therapy | $169.59 | $47.09 | 1 | 1 | Average annual cost from actual PBS expenditure on bloodpressure-lowering drugs in 2008 [23]. Mix of diuretics, beta-blockers, calcium channel blockers and ACE inhibitors based on BEACH general practice data [32]. |